Navigating CLL Management: Treatment Landscape, Patient Care, and Quality of Life - Episode 6
Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
September 13, 2024
The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with rituximab.
Video content above is prompted by the following:
- Can you explain what fixed-duration treatments are and how they differ from continuous therapy in CLL?
- Please briefly highlight venetoclax-based regimens, which are approved for 12 cycles in the frontline setting with obinutuzumab and 24 cycles in the relapsed/refractory setting with rituximab.?
Related Content:
